Ft. Worth, TX, United States of America

Paul Hallen

USPTO Granted Patents = 5 

Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 162(Granted Patents)


Company Filing History:


Years Active: 2005-2012

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Inventor Paul Hallen: Innovations in Ophthalmic Surgical Devices

Introduction

Paul Hallen, based in Ft. Worth, TX, is a prolific inventor known for his significant contributions to the field of ophthalmic surgical devices. With a total of five patents to his name, Hallen's work focuses primarily on developing innovative technologies to enhance surgical procedures, particularly for treating conditions such as Age Related Macular Degeneration (AMD).

Latest Patents

Hallen's latest patents include the "Beta Radiotherapy Emitting Surgical Device and Methods of Use Thereof" and the "Ophthalmic Treatment Apparatus." Both inventions revolve around a surgical device designed for the localized delivery of beta radiation in ophthalmic procedures. These devices feature a cannula equipped with beta radiotherapy emitting materials situated at the distal end, making them particularly effective for treating AMD.

Career Highlights

Throughout his career, Hallen has worked at notable companies, including Retinalabs, Inc. and Tdh Partners, Inc. His tenure in these organizations has allowed him to refine his ideas and bring innovative surgical solutions to life. His extensive experience in the medical field has positioned him as a leading figure in ophthalmic device technology.

Collaborations

Hallen's collaborative efforts include working alongside Eugene deJuan, a prominent figure in the industry. Their partnership has likely contributed to the success and development of advanced surgical devices that benefit patients undergoing ophthalmic procedures.

Conclusion

In summary, Paul Hallen stands out as an innovative inventor dedicated to improving surgical techniques in ophthalmology. His patents not only highlight his creativity and technical expertise but also represent a significant advancement in the treatment of Age Related Macular Degeneration. With a solid foundation in research and collaboration, Hallen continues to impact the field positively, paving the way for future innovations in medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…